CN1799650A - Method for preparing biodegradable drug-carried high molecular material stent - Google Patents
Method for preparing biodegradable drug-carried high molecular material stent Download PDFInfo
- Publication number
- CN1799650A CN1799650A CN 200510104766 CN200510104766A CN1799650A CN 1799650 A CN1799650 A CN 1799650A CN 200510104766 CN200510104766 CN 200510104766 CN 200510104766 A CN200510104766 A CN 200510104766A CN 1799650 A CN1799650 A CN 1799650A
- Authority
- CN
- China
- Prior art keywords
- support
- high molecular
- cradle
- tubing
- sacculus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 30
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 239000004626 polylactic acid Substances 0.000 claims abstract description 18
- 229920001610 polycaprolactone Polymers 0.000 claims abstract description 13
- 239000004632 polycaprolactone Substances 0.000 claims abstract description 13
- 230000019635 sulfation Effects 0.000 claims abstract description 9
- 238000005670 sulfation reaction Methods 0.000 claims abstract description 9
- 238000005530 etching Methods 0.000 claims abstract description 8
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims abstract description 6
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000001125 extrusion Methods 0.000 claims abstract description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 15
- 208000037803 restenosis Diseases 0.000 claims description 12
- 229920002521 macromolecule Polymers 0.000 claims description 8
- 229920001661 Chitosan Polymers 0.000 claims description 7
- 230000010100 anticoagulation Effects 0.000 claims description 7
- 229920000669 heparin Polymers 0.000 claims description 7
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 229960001008 heparin sodium Drugs 0.000 claims description 6
- 239000003055 low molecular weight heparin Substances 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000003698 laser cutting Methods 0.000 claims description 5
- 238000009434 installation Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims 2
- 238000002156 mixing Methods 0.000 abstract description 3
- LKAPTZKZHMOIRE-KVTDHHQDSA-N (2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbaldehyde Chemical compound OC[C@H]1O[C@H](C=O)[C@@H](O)[C@@H]1O LKAPTZKZHMOIRE-KVTDHHQDSA-N 0.000 abstract 2
- LKAPTZKZHMOIRE-UHFFFAOYSA-N chitose Natural products OCC1OC(C=O)C(O)C1O LKAPTZKZHMOIRE-UHFFFAOYSA-N 0.000 abstract 2
- 210000005077 saccule Anatomy 0.000 abstract 2
- 208000031481 Pathologic Constriction Diseases 0.000 abstract 1
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 230000002429 anti-coagulating effect Effects 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000009987 spinning Methods 0.000 abstract 1
- 208000037804 stenosis Diseases 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FTKOCAZZFUDHDQ-OXLBYMFNSA-N α-cam Chemical compound C([C@@H](N(CC1)C)C23C=C[C@@]4([C@H](C3)CN(CCCl)CCCl)OC)C3=CC=C(O)C5=C3[C@@]21[C@H]4O5 FTKOCAZZFUDHDQ-OXLBYMFNSA-N 0.000 description 2
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000578 dry spinning Methods 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229920006381 polylactic acid film Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The invention relates to a method for preparing a biodegradable cradle carrying medical high molecular material, with the technique program comprising: (1) mixing the degradable high molecular polylactic acid and polycaprolactone or polylactide according to the percentage by weight (100%: 0%)-(0%:100%); (2) adding anti-stenosis medicine of arsenic trioxide into the mixture above, making the mole volume concentration of the medicine be 0.001%-10%; (3)extrusion by melting with helical rotor or double screw, preparing the tubular goods with spinning board; (4) immersing the tubular goods in the carboxylated sulfation chitose solution with the mass volume concentration of 0.1%-20%, getting out and drying; (5) etching the tubular goods with cutting machine to net structure; (6) immersing in dimethy ketone solution for three to five times; (7) assembling the cradle with preassembling machine, making the cradle be adhesive to the saccule; (8) when the saccule expands, the shape of the opened cradle is high molecular cradle. The high molecular material used in this invention comprises polylactic acid, polylactide, and polycaprolactone, which is biodegradable. The partial low release of the medicine added in the cradle can act for a long time, the carboxylated sulfation chitose possesses good anticoagulant property, and by immersing the cradle in the high molecular cradle to realize different acting time by different medicine.
Description
One, technical field: the present invention relates to a kind of preparation method of biodegradable drug-carried high molecular material stent, belong to technical field of bioengineering.
Two, background technology: through the conduit interventional therapy is one of the most frequently used treatment means of vascular obstruction disease, and especially percutaneous puncture transluminal coronary angioplasty art (PTCA) is the very effective Therapeutic Method of coronary occlusion disease.The metal rack of present clinical use is a kind of foreign body to human body, and human body has rejection to it, and reaction and restenosis cause inflammation; And metal rack also can cause damage to ductus arteriosus wall, makes us that its secular safety is had doubt.Another problem of metal rack is to implant once more in position, or causes the implant surgery difficulty in its downstream to increase.Usually, when the patient falls ill again, have to adopt the heart bypass or claim bypass surgery.The degradable high polymer material support has better biocompatibility, and finally degradation in vivo disappears, and avoids the The Long-term Effect to human body.Macromolecular material can carry slow releasing pharmaceutical by means such as blend, spraying, absorption, scion graftings easily, reaches the purpose of anti-hemostasis-coagulation and restenosis.This support also can be used for his position of human body, is used to guarantee the unobstructed of various pipelines, and as urethra, bile duct etc.Tamai H etc. has reported the experimental result (CIRCULATION 102 (4): 399-404JUL 252000) in the polylactic acid bracket implant into body six months on the CIRCULATION magazine, this is the report that the degradable macromolecule support is applied to human body for the first time.In order better to prevent restenosis, research worker explore always various prevent restenosis method.Commonly used have radiation method, gene therapy, a medicament slow release method etc.Datta A etc. thank to build at patent EP Li Wen great waves and described a kind of band medicine degradable macromolecule support among the 0561-A2, and are two-layer inside and outside being divided into, and can carry different medicines, to regulate the slow release speed of medicine.The medicine of common anti-restenosis has taxol etc.The preparation of support is first filamentation, and is Wrapping formed again.Canesh R. makes the polylactic acid film forming with the method for spraying, and then is rolled into silk, but this silk is thick excessively, can not satisfy the demand (ASAIOJournal, M584,1994) of implant into body.L.Fambri etc. have obtained acid fiber by polylactic with melt spinning, but have serious signs of degradation, cause polymer molecular weight about 2/3 (Polymer Vol.38NO.1pp79-85,1997) that descend.Before this, L.Fambri etc. must be the fiber of polylactic acid with dry spinning, signs of degradation is also not serious, but there is the very poor problem of operability, be difficult to obtain long even filament (Journalof materials science:materials in medicine 679-683,5,1994), and be not easy to pore-creating on fiber.
Three, summary of the invention: purpose of the present invention is exactly the defective that exists at prior art, and a kind of preparation method of more safe and effective biodegradable drug-carried high molecular material stent is provided.
Its technical scheme comprises:
Method one
(1) be that fully mix (100%: 0%)-(0%: 100%) by mass percentage with the degradable macromolecule polylactic acid (PLLA) of tool certain molecular weight (intrinsic viscosity 0.5-9.0dl/g) and polycaprolactone (PCL) or polylactide (PGA);
(2) at said mixture, add anti-restenosis medicaments arsenic trioxide, making medicine molal volume concentration is 0.001%-10% (mol/ml);
(3) with the mixture of above-mentioned preparation,, melt extrude, and make tubing (internal diameter 0.1mm-45mm, external diameter 0.4mm-50mm) by special spinneret through single screw rod or twin screw melt extrusion equipment;
(4) with different-diameter, it is that the aqueous solution of carboxylated Sulfation chitosan of 0.1%-20% (g/ml) or the anticoagulation solution of Low molecular heparin sodium water solution and acetone (volume ratio) preparation in 1: 1 soak that the tubing of certain-length is put into the quality volumetric concentration, takes out airing; The also available spraying of solution is joined by institute, and tubing is carried out face coat;
(5) laser cutting machine is pressed the graphic design software design configuration, and computer control is etched into network structure with tubing down;
(6) support that etching is good soaks 3-5 time in acetone soln, and each soak time 10 seconds is to a few minutes;
(7) pre-installation is adopted in support assembling, and the sacculus of support and evacuation is heated (55-65 ℃) simultaneously, and support and sacculus are applied torsion along the tangent to periphery direction, and support is sticked on the sacculus.
(8) behind the balloon expandable, the form polymeric stent of stent open.
Method two
(1) be that fully mix (100%: 0%)-(0%: 100%) by mass percentage with the degradable macromolecule polylactic acid (PLLA) of tool certain molecular weight (intrinsic viscosity 0.5-9.0dl/g) and polycaprolactone (PCL) or polylactide (PGA);
(2) at said mixture, add anti-restenosis medicaments arsenic trioxide, making medicine molal volume concentration is 0.001%-10% (mol/ml);
(3) with the mixture of above-mentioned preparation,, melt extrude, and make tubing (internal diameter 0.1mm-45mm, external diameter 0.4mm-50mm) by special spinneret through single screw rod or twin screw melt extrusion equipment;
(4) laser cutting machine is pressed the graphic design software design configuration, and computer control is etched into network structure with tubing down;
(5) tubing of different-diameter, length being put into the quality volumetric concentration is that the aqueous solution of carboxylated Sulfation chitosan of 0.1%-20% (g/ml) or the anticoagulation solution of Low molecular heparin sodium water solution and acetone (volume ratio) preparation in 1: 1 soak, and takes out airing; The also available spraying of solution is joined by institute, and tubing is carried out face coat;
(6) support that etching is good soaks 3-5 time in acetone soln, and each soak time 10 seconds is to a few minutes;
(7) pre-installation is adopted in support assembling, and the sacculus of support and evacuation is heated (55-65 ℃) simultaneously, and support and sacculus are applied torsion along the tangent to periphery direction, and support is sticked on the sacculus.
(8) behind the balloon expandable, the form polymeric stent of stent open.
The used macromolecular material of the present invention comprises that polylactic acid (PLLA), polylactide (PGA), these materials of polycaprolactone (PCL) all are the high-molecular biologic degradation materials that can be used for human body through the medical practice proof.PLLA has good hardness strength character, adds the elasticity that a certain amount of PCL or PGA then can improve support, so use PLLA and the mixture of PCL or the mixture of PLLA and PGA in the skeleton of support.If add medicine in support, along with high molecular degraded, medicine just can be released in the blood.The local sustained release of this medicine both can be brought into play long curative effect, saved repeatedly external injection, also can make medicine that the side effect of other parts of health is dropped to minimum.In order to control the speed of medicament slow release, can add at rack surface and be coated with the medicine controlled-release coating.Carboxylated Sulfation chitosan and low molecular sodium heparin have good anticoagulation function, infiltrate in the polymeric stent by infusion method or spraying, by control solution concentration, soak time, can reach different drug treating times.
Four, description of drawings: do not have.
Five, specific embodiment:
Embodiment 1
(1) degradable macromolecule polylactic acid and the polycaprolactone with the tool certain molecular weight is fully mixing in 80%: 20% by mass percentage;
(2) at said mixture, add anti-restenosis medicaments arsenic trioxide, making medicine molal volume concentration is 0.05%mol/ml;
(3) with the mixture of above-mentioned preparation,, melt extrude, and make tubing (internal diameter 0.1mm-45mm, external diameter 0.4mm-50mm) by spinneret through single screw rod melt extrusion equipment;
(4) tubing of different-diameter can cut into different length as required;
(5) PROSTENT 1 laser cutting machine is pressed AlphaCAM (LICOM) graphic design software design configuration, and computer control is etched into the network structure form with tubing down;
(6) the good support of etching just, putting into the quality volumetric concentration is that the aqueous solution of the carboxylated Sulfation chitosan of 0.1%-20% (g/ml) soaks, and takes out airing;
(7) support that etching is good soaks 3-5 time in acetone soln, and each soak time 10 seconds is to a few minutes;
(8) support assembling adopts metal rack to install in advance, and the sacculus of support and evacuation is heated (60 ℃) simultaneously, and support and sacculus are applied torsion along the tangent to periphery direction, and support is sticked on the sacculus.
(9) behind the balloon expandable, stent open forms polymeric stent.
Embodiment 2
(1) degradable macromolecule polylactic acid (PLLA) and the polylactide (PGA) with tool certain molecular weight (intrinsic viscosity 0.5-9.0dl/g) is fully mixing in 70%: 30% by mass percentage;
(2) at said mixture, add anti-restenosis medicaments arsenic trioxide, making medicine molal volume concentration is 0.001%-10% (mol/ml);
(3) with the mixture of above-mentioned preparation,, melt extrude, and make tubing (internal diameter 0.1mm-45mm, external diameter 0.4mm-50mm) by special spinneret through twin screw melt extrusion equipment;
(4) tubing of different-diameter can cut into different length as required;
(5) PROSTENT 1 laser cutting machine is pressed AlphaCAM (LICOM) graphic design software design configuration, and computer control is etched into the network structure form with tubing down;
(6) network structure with different-diameter, length is the Low molecular heparin sodium water solution of 0.1%-20% (g/ml) and the anticoagulation spray solution of acetone (volume ratio) preparation in 1: 1 with the quality volumetric concentration, and the tubing network structure is carried out face coat;
(6) support that etching is good soaks 3-5 time in acetone soln, and each soak time 10 seconds is to a few minutes;
(7) support assembling adopts metal rack to install in advance, and the sacculus of support and evacuation is heated (55 ℃) simultaneously, and support and sacculus are applied torsion along the tangent to periphery direction, and support is sticked on the sacculus.
(8) behind the balloon expandable, the form polymeric stent of stent open.
Claims (3)
1, a kind of preparation method of biodegradable drug-carried high molecular material stent is characterized in that according to the following step:
(1) be that fully mix (100%: 0%)-(0%: 100%) by mass percentage with the degradable macromolecule polylactic acid of intrinsic viscosity 0.5-9.0dl/g and polycaprolactone or polylactide;
(2) at said mixture, add anti-restenosis medicaments, making medicine molal volume concentration is 0.001%-10%mol/ml;
(3) with the mixture of above-mentioned preparation, melt extrude, and make internal diameter 0.1mm-45mm, the tubing of external diameter 0.4mm-50mm by spinneret;
(4) with different-diameter, it is that the aqueous solution of carboxylated Sulfation chitosan of 0.1%-20%g/ml or the anticoagulation solution of Low molecular heparin sodium water solution and acetone preparation in 1: 1 by volume soak that the tubing of certain-length is put into the quality volumetric concentration, takes out airing;
(5) cutting machine is etched into the network structure support with tubing;
(6) support that etching is good soaks 3-5 time in acetone soln, and each soak time 10 seconds is to a few minutes;
(7) pre-installation is adopted in support assembling, to 55-65 ℃ of the sacculus heating of support and evacuation, simultaneously, support and sacculus is applied torsion along the tangent to periphery direction, and support is sticked on the sacculus;
(8) behind the balloon expandable, stent open forms.
2, a kind of preparation method of biodegradable drug-carried high molecular material stent is characterized in that according to the following step:
(1) be that fully mix (100%: 0%)-(0%: 100%) by mass percentage with the degradable macromolecule polylactic acid of intrinsic viscosity 0.5-9.0dl/g and polycaprolactone or polylactide;
(2) at said mixture, add anti-restenosis medicaments, making medicine molal volume concentration is 0.001%-10%mol/ml;
(3) with the mixture of above-mentioned preparation, melt extrude, and make internal diameter 0.1mm-45mm, the tubing of external diameter 0.4mm-50mm by spinneret;
(4) cutting machine is etched into the network structure support with tubing;
(5) with different-diameter, it is that the aqueous solution of carboxylated Sulfation chitosan of 0.1%-20%g/ml or the anticoagulation solution of Low molecular heparin sodium water solution and acetone preparation in 1: 1 by volume soak that the tubing of certain-length is put into the quality volumetric concentration, takes out airing;
(6) support that etching is good soaks 3-5 time in acetone soln, and each soak time 10 seconds is to a few minutes;
(7) pre-installation is adopted in support assembling, to 55-65 ℃ of the sacculus heating of support and evacuation, simultaneously, support and sacculus is applied torsion along the tangent to periphery direction, and support is sticked on the sacculus;
(8) behind the balloon expandable, stent open forms.
3, the preparation method of biodegradable drug-carried high molecular material stent according to claim 1 and 2 is characterized in that: described anti-restenosis medicaments is an arsenic trioxide; Be the aqueous solution of carboxylated Sulfation chitosan of 0.1%-20%g/ml or the anticoagulation solution of Low molecular heparin sodium water solution and acetone preparation in 1: 1 by volume with the quality volumetric concentration, with spraying on the tubing or be etched into cancellated support and carry out face coat; Described to melt extrude be to adopt single screw rod or twin screw melt extrusion equipment to melt extrude, and described cutting machine is a laser cutting machine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510104766 CN1799650B (en) | 2005-12-30 | 2005-12-30 | Method for preparing biodegradable drug-carried high molecular material stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510104766 CN1799650B (en) | 2005-12-30 | 2005-12-30 | Method for preparing biodegradable drug-carried high molecular material stent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1799650A true CN1799650A (en) | 2006-07-12 |
| CN1799650B CN1799650B (en) | 2010-07-14 |
Family
ID=36810008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510104766 Active CN1799650B (en) | 2005-12-30 | 2005-12-30 | Method for preparing biodegradable drug-carried high molecular material stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1799650B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103561791A (en) * | 2011-05-25 | 2014-02-05 | 科迪斯公司 | Expandable devices coated with a paclitaxel composition |
| CN107645930A (en) * | 2015-03-25 | 2018-01-30 | 伊西康有限责任公司 | Supporter is applied to the method for surgical stapling device |
| CN111246896A (en) * | 2018-01-09 | 2020-06-05 | 上海微特生物技术有限公司 | Degradable blood vessel stent capable of avoiding late restenosis |
| CN111803719A (en) * | 2020-05-28 | 2020-10-23 | 广州新诚生物科技有限公司 | Preparation method of degradable balloon and balloon prepared by using preparation method |
| CN113975593A (en) * | 2021-09-16 | 2022-01-28 | 上海市普陀区中心医院 | Kedalong medicine balloon and preparation method thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670161A (en) * | 1996-05-28 | 1997-09-23 | Healy; Kevin E. | Biodegradable stent |
| US6278079B1 (en) * | 1999-02-09 | 2001-08-21 | Edwards Lifesciences Corp. | Laser cutting of fabric grafts |
| CN2383533Y (en) * | 1999-06-09 | 2000-06-21 | 安泰科技股份有限公司 | Medical saccule blood vessel dilating internal supporter |
| CN1303947C (en) * | 2001-12-13 | 2007-03-14 | 华东理工大学 | Medicine eluted cardiovascular frame and its preparing process |
| CN1159071C (en) * | 2002-03-08 | 2004-07-28 | 清华大学 | Preparation method of biodegradable medicine composite macromolecular scaffold material |
| CN100374092C (en) * | 2005-01-14 | 2008-03-12 | 大连理工大学 | Medicinal coating production for vascular stand and electrostatic spraying apparatus |
| CN100435756C (en) * | 2005-01-31 | 2008-11-26 | 上海市第一人民医院 | Arsenic trioxide control release elution stent |
-
2005
- 2005-12-30 CN CN 200510104766 patent/CN1799650B/en active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103561791A (en) * | 2011-05-25 | 2014-02-05 | 科迪斯公司 | Expandable devices coated with a paclitaxel composition |
| CN103561791B (en) * | 2011-05-25 | 2016-03-23 | 科迪斯公司 | Be coated with the distensible devices of paclitaxel composition |
| CN107645930A (en) * | 2015-03-25 | 2018-01-30 | 伊西康有限责任公司 | Supporter is applied to the method for surgical stapling device |
| US11369380B2 (en) | 2015-03-25 | 2022-06-28 | Cilag Gmbh International | Method of applying a buttress to a surgical stapler |
| CN111246896A (en) * | 2018-01-09 | 2020-06-05 | 上海微特生物技术有限公司 | Degradable blood vessel stent capable of avoiding late restenosis |
| CN111803719A (en) * | 2020-05-28 | 2020-10-23 | 广州新诚生物科技有限公司 | Preparation method of degradable balloon and balloon prepared by using preparation method |
| CN113975593A (en) * | 2021-09-16 | 2022-01-28 | 上海市普陀区中心医院 | Kedalong medicine balloon and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1799650B (en) | 2010-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8021678B2 (en) | Implantable medical device with polymer coating in a surface area to volume ratio providing surface erosion characteristics | |
| EP0761251B1 (en) | Drug-releasing stent | |
| JP5377814B2 (en) | Medical instruments | |
| EP1454642B1 (en) | Stent with phenoxy primer coating | |
| EP1496814B1 (en) | Resorption-controllable medical implants | |
| CN109503797A (en) | A kind of medical degradable polyurethane and application thereof with antibacterial activity | |
| WO2017054433A1 (en) | Elastic modulus adjustable polyurethane composition, scaffold composite and preparation method thereof | |
| CA2638747A1 (en) | Combination drug therapy for reducing scar tissue formation | |
| WO2010104584A2 (en) | Articles and methods of treating vascular conditions | |
| US20060204537A1 (en) | Silicone blends and composites for drug delivery | |
| US9034355B2 (en) | Materials for modulating biological responses and methods of making | |
| CN1303947C (en) | Medicine eluted cardiovascular frame and its preparing process | |
| CN1799650A (en) | Method for preparing biodegradable drug-carried high molecular material stent | |
| CN105833358B (en) | Intracranial drug eluting stent system and preparation method thereof | |
| EP0652017B1 (en) | Coating for biomaterial | |
| US20140142686A1 (en) | Biodegradable stent formed with polymer-bioceramic nanoparticle composite and method of making the same | |
| CN1159071C (en) | Preparation method of biodegradable medicine composite macromolecular scaffold material | |
| CN107865868B (en) | New application of amlexanox | |
| CN102078229A (en) | Degradable coronary artery scaffold and preparation method thereof | |
| EP2146755B1 (en) | Device made at least partially of n-acetylchitosan with controlled biodissolution | |
| CN1524590A (en) | Medicament elution interventional medical apparatus and preparing method thereof | |
| CN1429547A (en) | Coronary artery skeleton medicinal coating for preventing restenosis of blood vessel | |
| Hiremath et al. | Safety and Efficacy of Drug-Eluting Stents Improved Dramatically with Application of Nanotechnology | |
| CN114082000B (en) | Biodegradable drug-loaded high polymer material stent and preparation method thereof | |
| CN109224139B (en) | Thermosensitive heart stent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANGHAI WEITE BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LI WENTAO Effective date: 20120906 Free format text: FORMER OWNER: XIE JIAN Effective date: 20120906 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 257000 DONGYING, SHANDONG PROVINCE TO: 201203 PUDONG NEW AREA, SHANGHAI |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120906 Address after: 406 B, room 201203, block 456, blue wave road, Shanghai, Pudong Patentee after: Shanghai Weite Biological Technology Co., Ltd. Address before: 257000 Shandong province Dongying city Ji'nan Road District No. 20-2-3 building Shengdong Patentee before: Li Wentao Patentee before: Xie Jian |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200630 Address after: No.009, Huihe Avenue, Kouzhen, Laiwu District, Jinan City, Shandong Province Patentee after: SHANDONG HUAAN BIOTECHNOLOGY Co.,Ltd. Address before: 406 B, room 201203, block 456, blue wave road, Shanghai, Pudong Patentee before: SHANGHAI WEITE BIOTECHNOLOGY Co.,Ltd. |